CACNG6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL116362	0.45	11/20
SCHEMBL6121858	0.52	9/20
SCHEMBL2585915	0.51	8/20
SCHEMBL3354274	0.62	7/20
SCHEMBL3357851	0.54	7/20
SCHEMBL4750473	0.52	7/20
SCHEMBL3350921	0.49	7/20
SCHEMBL619154	0.41	7/20
SCHEMBL620978	0.40	7/20
SCHEMBL621013	0.40	7/20
SCHEMBL5428566	0.52	6/20
SCHEMBL621555	0.39	6/20
SCHEMBL617973	0.38	6/20
SCHEMBL7053553	0.62	5/20
SCHEMBL4405461	0.55	5/20
SCHEMBL4399845	0.54	5/20
SCHEMBL4967687	0.51	5/20
SCHEMBL1810921	0.51	5/20
SCHEMBL4399843	0.50	5/20
SCHEMBL3477582	0.47	5/20

Clinical trials — most relevant to CACNG6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination	PHASE4	UNKNOWN
Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children	PHASE4	UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
The Re-Prosper HF Study	PHASE2/PHASE3	COMPLETED
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain	PHASE2	COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients	PHASE2	WITHDRAWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
Physiologic Effects of Topiramate on Cognition	PHASE1	COMPLETED
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption	nan	COMPLETED
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
ST-segment Elevation as an AF Endophenotype	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Evaluation of A Clinical Diagnostic Test for CRDS	nan	RECRUITING
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
Neurogenetic And Hemodynamic Of Migraine Aura And Pfo	nan	RECRUITING
Neurogenic Mechanisms in Burning Mouth Syndrome	nan	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Rolandic Epilepsy Genomewide Association International Study	nan	COMPLETED
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	nan	RECRUITING
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation.	nan	UNKNOWN
Clinical-genetic Investigations in Children With Early Infantile Epilepsies	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNG6 binder may also engage these)

Protein	Name	Similarity
Q8VHW7	—	0.990	Q8VHW7 →
Q8VHW3	—	0.987	Q8VHW3 →
Q9CZ16	—	0.979	Q9CZ16 →
Q8NBL3	—	0.974	Q8NBL3 →
Q68FV0	—	0.973	Q68FV0 →
Q9D563	—	0.972	Q9D563 →
B3SHH9	—	0.971	B3SHH9 →
F6V1J6	—	0.968	F6V1J6 →
Q08DE1	—	0.968	Q08DE1 →
CACNG1	Voltage-dependent calcium channel gamma-1 sub	0.960	landscape →
Q5XGU1	—	0.957	Q5XGU1 →
Q14714	—	0.955	Q14714 →
P82352	—	0.954	P82352 →
O70578	—	0.954	O70578 →
Q2MJQ7	—	0.953	Q2MJQ7 →
P19518	—	0.953	P19518 →
Q08CE6	—	0.952	Q08CE6 →
Q969K7	—	0.952	Q969K7 →
P97707	—	0.950	P97707 →
Q3ZCD2	—	0.950	Q3ZCD2 →
Q62147	—	0.949	Q62147 →
Q4R4Z3	—	0.942	Q4R4Z3 →
Q9BSN7	—	0.942	Q9BSN7 →
B2RVY9	—	0.942	B2RVY9 →
A4IF75	—	0.940	A4IF75 →
P51810	—	0.940	P51810 →
Q6UXU4	—	0.940	Q6UXU4 →
Q5RDV7	—	0.940	Q5RDV7 →
Q9NY35	—	0.940	Q9NY35 →
Q9CQX5	—	0.939	Q9CQX5 →